AMGEN INC (AMGN)
AMGEN INC (AMGN) from its SEC filings: 2025 revenue $36.8 billion (+10% vs the year before), net margin 21%, free cash flow $8.1 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $36.8 billion |
| Revenue growth | +10% |
| Net income | $7.7 billion |
| Net margin | 21.0% |
| Free cash flow | $8.1 billion |
| Diluted EPS | $14.23 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $14.0 billion |
| Long-term debt | $51.9 billion |
| Share count, 1 year | +0% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.